Amid EpiPen shortage concerns, a mixed bag of first quarter financials for Mylan

Netherlands-incorporated Mylan has reported first quarter revenues of $2.7 billion, down 1% compared…

More From BioPortfolio on "Amid EpiPen shortage concerns, a mixed bag of first quarter financials for Mylan"